RTW Investments Acquires $192.59 Million Stake in Apellis Pharmaceuticals

AI Summary

RTW Investments has initiated a new stake in Apellis Pharmaceuticals (NASDAQ: APLS) by acquiring 7,666,764 shares worth $192.59 million, according to a February 17, 2026, SEC filing. Apellis reported a total revenue of approximately $689 million last year, with a market capitalization of $2.2 billion. The stock is currently priced at $17.21, reflecting a 29% decline over the past year, underperforming the S&P 500's 15% increase. This significant investment in Apellis, which produces treatments for rare diseases, could influence market perceptions of biotech investments.